Market Overview

Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech

Share:
Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
Related MYL
Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts
Benzinga's Top Upgrades, Downgrades For August 22, 2017
Related VRX
GlassHouse: NuVasive Using The 'Valeant Playbook' To Deceive Investors
Watch These 8 Huge Put Purchases In Tuesday Trade

Drug pricing has been one of the hot topics of the year. As Citron Research's controversial executive editor Andrew Left said last month, “Regulating the price of pharmaceuticals and eliminating price gouging might be the only issue that Trump and Hillary both agree on.”

Conversing with SunTrust Robinson Humphrey Managing Director and Senior Biotechnology Analyst Edward Nash and Associate Biotechnology Analyst Mike Guo, Benzinga had the chance to discuss drug pricing, an issue that goes well beyond Valeant Pharmaceuticals Intl Inc (NYSE: VRX), Mylan NV (NASDAQ: MYL) or Martin Shkreli.

Related Link: Exclusive: SunTrust Top Analysts Explain Fatty Liver Diseases, Galmed's Potential In The Space

“If you look at what we’ve seen in the last year-and-a-half or two years, the issues that have popped up around pricing, have always been with older drugs that have been out there for a while, which have been rebranded, or had their patents extended, or just don’t have any competition… and they’ve had their prices dramatically increased overnight,” Nash explained. So, controversy in these cases is quite easy to understand.

However, the expert added, this is not considered biotech. “At some point, that is going to be the low hanging fruit… and that kind of gouging (if you want to call it that, which in some cases, it is) is where I think we would start to see the first, initial attempts to make some type of pricing changes there.”

Related Link: Exclusive: SunTrust Managing Director Goes Over Sarepta Therapeutics' Story

Nonetheless, he went on:

    1. “Any changes that would come about… won’t happen overnight… It takes time and a lot of work.”
    2. Companies in the biotech space, developing drugs that are the first approved for an indication, or drugs that target orphan indications, or drugs that offer much higher levels of efficacy or safety than pre-existing treatments, will always be able to charge a premium.

“So, normal biotech, while it does get affected by rumors and talk [about price gouging],” would not feel a big impact over the near or longer term. Instead, Nash concluded, this is something that would have a larger impact on specialty pharmaceuticals and generics pharmaceuticals first.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Disclosure: Javier Hasse holds no interest in any of the securities or entities mentioned above.

 

Latest Ratings for MYL

DateFirmActionFromTo
Aug 2017ArgusDowngradesBuyHold
Aug 2017CitigroupUpgradesNeutralBuy
Aug 2017Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Short Sellers Health Care Politics Analyst Ratings Trading Ideas Interview Best of Benzinga

 

Related Articles (BBH + FBT)

View Comments and Join the Discussion!
Loading...
Loading...